Adenovirally delivered IFN-β exerts antitumor effects through transient T-lymphocyte depletion and Ag-specific T-cell proliferation

Sang Seok Oh, Chaerin Moon, Dong Hyeok Kim, Hyunkeun Song, Saegwang Park, Yangxin Fu, Kwang Dong Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Type I interferons (IFNs), including IFN-β, are known to enhance antigen (Ag) presentation and to promote the expansion, survival and effector function of CD8 + cytotoxic lymphocytes (CTL) during viral infections. Furthermore, IFN-β is a potent candidate for antitumor drugs; however, recombinant IFN-β is too unstable for use in tumor therapy in vivo. In this study, we therefore examined the efficacy and mechanism of exogenous IFN-β as a biomolecule for tumor therapy, using adenovirus encoding IFN-β (Ad-IFNβ) as a therapeutic agent in a mouse model. Ag104L d and 4T1 tumor cells exposed to Ad-IFNβ showed growth retardation and cell death in vitro, and tumor growth as well as tumor metastasis was inhibited in vivo. The Ad-IFNβ-mediated antitumor effect was dependent on CD8 + T cells in vivo, rather than on a direct cytotoxic effect of Ad-IFNβ. Transient T lymphocyte depletion was observed in tumor tissue after intratumoral injection with Ad-IFNβ. Despite the T lymphocyte depletion, the proliferation of Ag-specific CD8 + T cells was increased in Ad-IFNβ-treated mice compared to control virus-treated mice. These results suggest that IFN-β might contribute to the inhibition of tumor growth by depleting Ag-nonspecific T lymphocytes and enhancing proliferation of Ag-specific CD8 + T cells.

Original languageEnglish (US)
Pages (from-to)1153-1157
Number of pages5
JournalInternational Journal of Molecular Medicine
Volume29
Issue number6
DOIs
StatePublished - Jun 1 2012

Fingerprint

Lymphocyte Depletion
Viral Tumor Antigens
Interferons
Adenoviridae
Cell Proliferation
T-Lymphocytes
Neoplasms
CD8 Antigens
Growth
Interferon Type I
Antigen Presentation
Virus Diseases
Antineoplastic Agents
Cell Death
Therapeutics
Lymphocytes
Neoplasm Metastasis
Viruses
Antigens
Injections

Keywords

  • Adenovirus encoding IFN-β
  • Antigen-specific CD8 T cell
  • Transient T lymphocyte depletion
  • Tumor therapy

ASJC Scopus subject areas

  • Genetics

Cite this

Adenovirally delivered IFN-β exerts antitumor effects through transient T-lymphocyte depletion and Ag-specific T-cell proliferation. / Oh, Sang Seok; Moon, Chaerin; Kim, Dong Hyeok; Song, Hyunkeun; Park, Saegwang; Fu, Yangxin; Kim, Kwang Dong.

In: International Journal of Molecular Medicine, Vol. 29, No. 6, 01.06.2012, p. 1153-1157.

Research output: Contribution to journalArticle

Oh, Sang Seok ; Moon, Chaerin ; Kim, Dong Hyeok ; Song, Hyunkeun ; Park, Saegwang ; Fu, Yangxin ; Kim, Kwang Dong. / Adenovirally delivered IFN-β exerts antitumor effects through transient T-lymphocyte depletion and Ag-specific T-cell proliferation. In: International Journal of Molecular Medicine. 2012 ; Vol. 29, No. 6. pp. 1153-1157.
@article{76291593bf7845b0bcae484ac2562fba,
title = "Adenovirally delivered IFN-β exerts antitumor effects through transient T-lymphocyte depletion and Ag-specific T-cell proliferation",
abstract = "Type I interferons (IFNs), including IFN-β, are known to enhance antigen (Ag) presentation and to promote the expansion, survival and effector function of CD8 + cytotoxic lymphocytes (CTL) during viral infections. Furthermore, IFN-β is a potent candidate for antitumor drugs; however, recombinant IFN-β is too unstable for use in tumor therapy in vivo. In this study, we therefore examined the efficacy and mechanism of exogenous IFN-β as a biomolecule for tumor therapy, using adenovirus encoding IFN-β (Ad-IFNβ) as a therapeutic agent in a mouse model. Ag104L d and 4T1 tumor cells exposed to Ad-IFNβ showed growth retardation and cell death in vitro, and tumor growth as well as tumor metastasis was inhibited in vivo. The Ad-IFNβ-mediated antitumor effect was dependent on CD8 + T cells in vivo, rather than on a direct cytotoxic effect of Ad-IFNβ. Transient T lymphocyte depletion was observed in tumor tissue after intratumoral injection with Ad-IFNβ. Despite the T lymphocyte depletion, the proliferation of Ag-specific CD8 + T cells was increased in Ad-IFNβ-treated mice compared to control virus-treated mice. These results suggest that IFN-β might contribute to the inhibition of tumor growth by depleting Ag-nonspecific T lymphocytes and enhancing proliferation of Ag-specific CD8 + T cells.",
keywords = "Adenovirus encoding IFN-β, Antigen-specific CD8 T cell, Transient T lymphocyte depletion, Tumor therapy",
author = "Oh, {Sang Seok} and Chaerin Moon and Kim, {Dong Hyeok} and Hyunkeun Song and Saegwang Park and Yangxin Fu and Kim, {Kwang Dong}",
year = "2012",
month = "6",
day = "1",
doi = "10.3892/ijmm.2012.936",
language = "English (US)",
volume = "29",
pages = "1153--1157",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Adenovirally delivered IFN-β exerts antitumor effects through transient T-lymphocyte depletion and Ag-specific T-cell proliferation

AU - Oh, Sang Seok

AU - Moon, Chaerin

AU - Kim, Dong Hyeok

AU - Song, Hyunkeun

AU - Park, Saegwang

AU - Fu, Yangxin

AU - Kim, Kwang Dong

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Type I interferons (IFNs), including IFN-β, are known to enhance antigen (Ag) presentation and to promote the expansion, survival and effector function of CD8 + cytotoxic lymphocytes (CTL) during viral infections. Furthermore, IFN-β is a potent candidate for antitumor drugs; however, recombinant IFN-β is too unstable for use in tumor therapy in vivo. In this study, we therefore examined the efficacy and mechanism of exogenous IFN-β as a biomolecule for tumor therapy, using adenovirus encoding IFN-β (Ad-IFNβ) as a therapeutic agent in a mouse model. Ag104L d and 4T1 tumor cells exposed to Ad-IFNβ showed growth retardation and cell death in vitro, and tumor growth as well as tumor metastasis was inhibited in vivo. The Ad-IFNβ-mediated antitumor effect was dependent on CD8 + T cells in vivo, rather than on a direct cytotoxic effect of Ad-IFNβ. Transient T lymphocyte depletion was observed in tumor tissue after intratumoral injection with Ad-IFNβ. Despite the T lymphocyte depletion, the proliferation of Ag-specific CD8 + T cells was increased in Ad-IFNβ-treated mice compared to control virus-treated mice. These results suggest that IFN-β might contribute to the inhibition of tumor growth by depleting Ag-nonspecific T lymphocytes and enhancing proliferation of Ag-specific CD8 + T cells.

AB - Type I interferons (IFNs), including IFN-β, are known to enhance antigen (Ag) presentation and to promote the expansion, survival and effector function of CD8 + cytotoxic lymphocytes (CTL) during viral infections. Furthermore, IFN-β is a potent candidate for antitumor drugs; however, recombinant IFN-β is too unstable for use in tumor therapy in vivo. In this study, we therefore examined the efficacy and mechanism of exogenous IFN-β as a biomolecule for tumor therapy, using adenovirus encoding IFN-β (Ad-IFNβ) as a therapeutic agent in a mouse model. Ag104L d and 4T1 tumor cells exposed to Ad-IFNβ showed growth retardation and cell death in vitro, and tumor growth as well as tumor metastasis was inhibited in vivo. The Ad-IFNβ-mediated antitumor effect was dependent on CD8 + T cells in vivo, rather than on a direct cytotoxic effect of Ad-IFNβ. Transient T lymphocyte depletion was observed in tumor tissue after intratumoral injection with Ad-IFNβ. Despite the T lymphocyte depletion, the proliferation of Ag-specific CD8 + T cells was increased in Ad-IFNβ-treated mice compared to control virus-treated mice. These results suggest that IFN-β might contribute to the inhibition of tumor growth by depleting Ag-nonspecific T lymphocytes and enhancing proliferation of Ag-specific CD8 + T cells.

KW - Adenovirus encoding IFN-β

KW - Antigen-specific CD8 T cell

KW - Transient T lymphocyte depletion

KW - Tumor therapy

UR - http://www.scopus.com/inward/record.url?scp=84860537877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860537877&partnerID=8YFLogxK

U2 - 10.3892/ijmm.2012.936

DO - 10.3892/ijmm.2012.936

M3 - Article

VL - 29

SP - 1153

EP - 1157

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 6

ER -